A detailed history of Bard Associates Inc transactions in Harrow Health, Inc. stock. As of the latest transaction made, Bard Associates Inc holds 69,880 shares of HROW stock, worth $1.46 Million. This represents 0.35% of its overall portfolio holdings.

Number of Shares
69,880
Previous 66,050 5.8%
Holding current value
$1.46 Million
Previous $739,000 25.03%
% of portfolio
0.35%
Previous 0.29%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$9.3 - $13.23 $35,619 - $50,670
3,830 Added 5.8%
69,880 $924,000
Q4 2023

Feb 13, 2024

BUY
$8.1 - $16.36 $4,860 - $9,816
600 Added 0.92%
66,050 $739,000
Q2 2023

Aug 11, 2023

SELL
$17.37 - $28.08 $730,842 - $1.18 Million
-42,075 Reduced 39.13%
65,450 $1.25 Million
Q1 2023

May 12, 2023

SELL
$13.84 - $21.46 $2,768 - $4,292
-200 Reduced 0.19%
107,525 $2.28 Million
Q3 2022

Nov 09, 2022

SELL
$6.57 - $24.88 $11,924 - $45,157
-1,815 Reduced 1.66%
107,725 $1.3 Million
Q2 2022

Aug 11, 2022

BUY
$5.75 - $7.74 $140,300 - $188,856
24,400 Added 28.66%
109,540 $797,000
Q4 2021

Feb 14, 2022

SELL
$8.5 - $12.0 $25,500 - $36,000
-3,000 Reduced 3.4%
85,140 $736,000
Q3 2021

Nov 12, 2021

BUY
$6.99 - $10.6 $12,756 - $19,345
1,825 Added 2.11%
88,140 $801,000
Q2 2021

Aug 12, 2021

BUY
$6.68 - $11.07 $99,699 - $165,219
14,925 Added 20.91%
86,315 $802,000
Q1 2021

May 13, 2021

BUY
$6.26 - $11.03 $87,264 - $153,758
13,940 Added 24.26%
71,390 $482,000
Q4 2019

Feb 13, 2020

BUY
$4.6 - $7.88 $264,270 - $452,706
57,450 New
57,450 $447,000
Q4 2019

Feb 13, 2020

SELL
$4.6 - $7.88 $268,870 - $460,586
-58,450 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$4.89 - $8.0 $33,741 - $55,200
6,900 Added 13.39%
58,450 $328,000
Q1 2019

May 13, 2019

BUY
$4.75 - $7.1 $244,862 - $366,005
51,550 New
51,550 $257,000

Others Institutions Holding HROW

About HARROW HEALTH, INC.


  • Ticker HROW
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 27,070,000
  • Market Cap $565M
  • Description
  • Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...
More about HROW
Track This Portfolio

Track Bard Associates Inc Portfolio

Follow Bard Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bard Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Bard Associates Inc with notifications on news.